Journal article icon

Journal article

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Abstract:

Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41598-021-95150-z

Authors


Publisher:
Springer Nature
Journal:
Scientific Reports More from this journal
Volume:
11
Article number:
15694
Publication date:
2021-08-03
Acceptance date:
2021-07-20
DOI:
EISSN:
2045-2322
Language:
English
Keywords:
Pubs id:
1187396
Local pid:
pubs:1187396
Deposit date:
2021-07-23

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP